Omnicef (cefdinir) is a broad-spectrum, third-generation oral cephalosporin antibiotic prescribed for the treatment of a wide range of susceptible bacterial infections. It functions by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. This medication is indicated for both adult and pediatric patients, offering a well-tolerated option with a convenient once or twice-daily dosing regimen. Its efficacy against common pathogens makes it a frontline choice for community-acquired respiratory, skin, and soft tissue infections.

Features

• Active ingredient: Cefdinir
• Drug class: Third-generation cephalosporin antibiotic
• Available formulations: Capsules (300 mg) and oral suspension (125 mg/5 mL, 250 mg/5 mL)
• Dosing frequency: Once or twice daily, depending on indication and severity
• Broad-spectrum activity against Gram-positive and Gram-negative bacteria
• FDA-approved for use in patients 6 months and older

Benefits

• Effective eradication of common bacterial pathogens causing respiratory, skin, and ear infections
• Convenient dosing schedule enhances patient adherence and compliance
• Generally well-tolerated profile with a lower incidence of severe adverse effects compared to some alternative antibiotics
• Suitable for pediatric populations, with a palatable oral suspension formulation
• Does not require refrigeration after reconstitution, improving portability and ease of use
• Minimal interference with cytochrome P450 enzyme system, reducing potential for certain drug interactions

Common use

Omnicef is commonly prescribed for the treatment of mild to moderate bacterial infections caused by susceptible strains of microorganisms. Key indications include acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, acute maxillary sinusitis, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, and acute bacterial otitis media. It demonstrates particular efficacy against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes, and Staphylococcus aureus (methicillin-susceptible strains only).

Dosage and direction

Dosage varies based on infection type, severity, patient age, and renal function. For most infections in adults and adolescents, the recommended dose is 300 mg every 12 hours or 600 mg once daily for 5-10 days. Pediatric dosing is based on weight: 7 mg/kg every 12 hours or 14 mg/kg once daily. Oral suspension should be shaken well before each use. Omnicef may be taken with or without food; however, administration with food may enhance tolerability if gastrointestinal upset occurs. Patients with impaired renal function (creatinine clearance <30 mL/min) require dosage adjustment, typically 300 mg once daily.

Precautions

Patients should complete the entire prescribed course of therapy even if symptoms improve to prevent development of antibiotic resistance. Use with caution in patients with gastrointestinal disease, particularly colitis. May cause false-positive reactions for glucose in urine with certain testing methods (Benedict’s solution, Fehling’s solution). As with other broad-spectrum antibiotics, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Monitor for signs of superinfection. Use in pregnancy only if clearly needed (Category B). Cefdinir is excreted in human milk; caution should be exercised when administering to nursing women.

Contraindications

Omnicef is contraindicated in patients with known hypersensitivity to cefdinir, other cephalosporins, or any component of the formulation. Cross-sensitivity with penicillin-class antibiotics may occur; avoid use in patients with history of severe hypersensitivity reactions (anaphylaxis) to penicillins. Not recommended for patients with inborn errors of metabolism that cause phenylketonuria (suspension contains aspartame).

Possible side effect

The most commonly reported adverse reactions include diarrhea (up to 8%), nausea (3%), vaginal moniliasis (3%), headache (2%), and abdominal pain (1%). Less frequent side effects may include rash, vomiting, dyspepsia, flatulence, dizziness, and elevated liver enzymes. Serious but rare adverse effects include pseudomembranous colitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, hemolytic anemia, and serum sickness-like reactions. The oral suspension may cause temporary discoloration of teeth (yellow, brown, or gray); usually removable with professional dental cleaning.

Drug interaction

Antacids containing magnesium or aluminum and iron supplements may significantly reduce cefdinir absorption; administer at least 2 hours apart. Probenecid may decrease renal excretion of cefdinir, potentially increasing serum concentrations. False-positive urine glucose tests may occur with certain reagents. No clinically significant interactions with warfarin have been reported, but monitoring is recommended when initiating concomitant therapy.

Missed dose

If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining consistent antibiotic levels is important for efficacy, so patients should strive for adherence to the prescribed regimen.

Overdose

In case of suspected overdose, symptomatic and supportive treatment is recommended. Gastric lavage may be considered if performed soon after ingestion. Cefdinir is eliminated primarily by the kidneys; hemodialysis may accelerate removal in cases of significant overdose (removes approximately 63% of dose over 4 hours). Monitor renal function and provide appropriate electrolyte replacement if diarrhea occurs. There is no specific antidote for cefdinir overdose.

Storage

Store capsules at controlled room temperature (20-25°C or 68-77°F) in a tight container. Keep oral suspension powder at room temperature before reconstitution. After reconstitution with water, store in tight container at room temperature or refrigerate (2-8°C or 36-46°F); discard unused portion after 10 days. Do not freeze. Keep all medications out of reach of children and pets.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Omnicef is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to therapy may vary. Always consult with a healthcare provider for proper diagnosis, treatment recommendations, and personalized medical advice. Do not initiate, adjust, or discontinue medication without professional guidance.

Reviews

Clinical studies demonstrate Omnicef’s efficacy with clinical cure rates of 85-95% for various indications. In comparative trials, cefdinir showed equivalent efficacy to amoxicillin/clavulanate, cefuroxime axetil, and cephalexin with generally improved tolerability. Healthcare providers frequently note the convenience of once-daily dosing and low incidence of gastrointestinal side effects compared to other antibiotics. Pediatricians appreciate the palatability of the suspension formulation and acceptance among young patients. Some reports note the potential for stool discoloration (reddish) due to formation of a non-absorbable complex with iron, which is harmless but may cause concern if not anticipated.